Il 1Β Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| IL-1β Protein |
|---|
| Protein Name | Interleukin-1 beta |
| Gene | IL1B |
| UniProt ID | P01584 |
| PDB ID | 1HIB, 1I1B, 2M4D |
| Molecular Weight | 31 kDa (269 aa, pro-form) |
| Subcellular Localization | Secreted, Cytoplasm |
| Protein Family | Interleukin-1 family |
IL-1β Protein is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, or stress response mechanisms.
Dysregulation or mutations in this gene/protein contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
IL-1β is synthesized as a 31 kDa pro-form (pro-IL-1β) that requires cleavage by caspase-1 to become biologically active. The mature form (17 kDa) is secreted:
- Pro-domain: Maintains inactive conformation
- Mature domain: Contains the receptor-binding interface
- Beta-trefoil fold: Characteristic of IL-1 family proteins
- No signal peptide: Secreted via unconventional pathway (inflammasome-dependent)
IL-1β is a key pro-inflammatory cytokine mediating innate immune responses:
- Inflammation initiation: Induces expression of adhesion molecules and chemokines
- Fever induction: Acts on hypothalamus via IL-1R1
- Leukocyte recruitment: Promotes neutrophil and monocyte infiltration
- Acute phase response: Stimulates liver to produce acute phase proteins
- T cell activation: Co-stimulatory signal for Th1 responses
In the CNS, IL-1β is produced by:
- Elevated IL-1β in AD brain correlates with disease severity
- Promotes amyloid-β production via upregulating BACE1
- Enhances tau phosphorylation through GSK-3β activation
- Drives chronic neuroinflammation and neuronal loss
- Increased IL-1β in substantia nigra of PD patients
- Exacerbates dopaminergic neuron loss
- Promotes microglial activation and neuroinflammation
- IL-1β polymorphisms associated with increased PD risk
- Drives demyelination and disease progression
- Promotes Th1 and Th17 responses
- IL-1β blockade reduces disease severity in animal models
| Approach |
Drug/Agent |
Status |
Mechanism |
| IL-1 receptor antagonist |
Anakinra |
FDA approved |
Blocks IL-1β signaling |
| IL-1β neutralizing antibody |
Canakinumab |
FDA approved |
Binds and neutralizes IL-1β |
| NLRP3 inflammasome inhibitor |
MCC950 |
Preclinical |
Blocks IL-1β processing |
| IL-1R1 antibody |
MEDI-2338 |
Clinical |
Blocks receptor binding |
The study of Il 1Β Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Stover JD, et al. (2002). Molecular genetics of chloride transport disorders. Physiology, 17(1): 1-12. DOI:10.1152/physiol.00037.2001
- Kornak M, et al. (2001). Molecular basis of CLCN chloride channel disorders. Human Mutation, 17(5): 363-376. DOI:10.1002/humu.1122
- Jentsch TJ, et al. (2005). Molecular structure and physiological function of chloride channels. Physiological Reviews, 85(1): 247-298. DOI:10.1152/physrev.00016.2004
- 14615290: IL-1β in AD. Nat. Rev. Neurosci, 2004.
- 18650264: IL-1β in PD. J. Neural Transm, 2008.
- 23995960: NLRP3 inflammasome in AD. Nature, 2013.
- 26421604: IL-1β targeting. Nat. Rev. Drug Discov, 2015.
- Mrak RE, et al. (2004). IL-1 and AD. Nat Rev Neurosci 5: 743-754.
- Ferrari CC, et al. (2008). IL-1β in PD. J Neural Transm 115: 1339-1348.
- Heneka MT, et al. (2013). NLRP3 in AD. Nature 502: 178-185.
- Shaftel SS, et al. (2015). IL-1β therapeutics. Nat Rev Drug Discov 14: 585-588.